Coagulation factor VIIa (recombinant)

Coagulation factor VIIa (recombinant) is a protein that is used in the treatment of hemophilia and other bleeding disorders. It is a recombinant DNA product, meaning it is produced through genetic engineering techniques.

Overview[edit | edit source]

Coagulation factor VIIa is a protein involved in the coagulation cascade, a series of reactions that ultimately leads to the formation of a blood clot. In individuals with certain bleeding disorders, such as hemophilia, this protein may be deficient or dysfunctional, leading to excessive bleeding. Recombinant factor VIIa is used to replace the deficient or dysfunctional protein, helping to control bleeding.

Production[edit | edit source]

Recombinant factor VIIa is produced using recombinant DNA technology. The gene for factor VIIa is inserted into a host organism, typically a type of yeast or bacteria, which then produces the protein. This protein is then purified and formulated into a product that can be administered to patients.

Uses[edit | edit source]

Recombinant factor VIIa is used in the treatment of bleeding disorders, most commonly hemophilia. It is used in patients with hemophilia A or B who have developed inhibitors, or antibodies, against the factor VIII or IX products they normally receive. It can also be used in patients with other rare bleeding disorders, such as factor VII deficiency.

Side Effects[edit | edit source]

Like all medications, recombinant factor VIIa can have side effects. These can include reactions at the injection site, fever, and an increased risk of blood clots. Patients are monitored closely for these and other potential side effects.